Medical Bulletin 12/December/2022

Urinary incontinence is a common complaint among adults with severe obesity. The majority of adults with urinary incontinence who undergo Roux-en-Y gastric bypass or sleeve gastrectomy, the two most common types of weight loss surgery, can reasonably expect enduring improvements in urinary incontinence, according to a new study published in JAMA Network Open.

Wendy C. King, Ph.D., epidemiologist at the University of Pittsburgh School of Public Health, and colleagues followed 1,227 men and women enrolled in the Longitudinal Assessment of Bariatric Surgery-2 study. Participants, who had a median age of 46 prior to surgery, were surveyed about urinary incontinence episode frequency before and annually after surgery.

Reference:

Wendy C. King et al,Seven-Year Durability of Improvements in Urinary Incontinence After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy,JAMA Network Open, DOI 10.1001/jamanetworkopen.2022.46057

Large reduction in premature death risk by doing just one-minute bursts of physical activity: Study

In good news for those who don't like playing sport or going to the gym, new research finds just three to four one-minute bursts of huffing and puffing during daily tasks is associated with large reductions in the risk of premature death, particularly from cardiovascular disease.

Published in Nature Medicine today, the study is led by the University of Sydney's Charles Perkins Centre in Australia. It is the first to accurately measure the health benefits of what researchers have termed 'vigorous intermittent lifestyle physical activity' or VILPA.

Reference:

Emmanuel Stamatakis, et al,Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality, Nature Medicine, DOI

10.1038/s41591-022-02100-x

Monoclonal antibody therapy treatment for moderate to severe atopic dermatitis shows promise: Mount Sinai Research

Eczema, also known as atopic dermatitis, is a disorder that results in dry, itchy, and inflamed skin. Although it can happen to anyone, it is more frequent in young children. Atopic dermatitis is persistent (chronic) and occasionally flares up. Although it is not contagious, it can be unpleasant.

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-a novel, patient-tailored monoclonal antibody therapy-showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.

Reference:

Emma Guttman et al, The Lancet, DOI 0.1016/S0140-6736(22)02037-2

73 percent of patients in two clinical trials exhibit success in experimental cancer therapy

Nearly all patients with myeloma who receive standard therapies continually relapse. Patients who relapse or become resistant to all approved multiple myeloma therapies have a poor prognosis, so additional treatments are urgently needed.

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

Reference:

Ajai Chari et al, THE MOUNT SINAI HOSPITAL / MOUNT SINAI SCHOOL OF MEDICINE, JOURNAL: New England Journal of Medicine